Vancouver, British Columbia – January 27, 2022 – Origin Therapeutics Holdings Inc. (CSE: ORIG Proposed) (the “Company” or “Origin Therapeutics”) an actively managed investment issuer focused on making equity investments in psychedelics-related companies, applauds the recent move by Health Canada that came into effect this month, authorizing physicians to prescribe medicinal psychedelic drug treatments.
The federal regulations were amended under Health Canada’s Special Access Program. Under that program, a patient can be approved for treatment if conventional approaches are unavailable, unsuitable, or have not worked. This could be for conditions such as PTSD or depression. The amendment expands access to MDMA and psilocybin therapy, just as has been done with ketamine therapy.
“This is an exciting day for the millions of Canadians that suffer from serious mental illness and related issues, as well as for those people who love and care about those individuals,” said Alexander Somjen, CEO of Origin Therapeutics, which is focused on identifying and investing in private, early-stage companies in the psychedelics industry. “The data clearly shows that these treatments are helping people. And now more than ever, with the ongoing COVID-19 pandemic continuing to disrupt so many lives, there has been an additional need for mental health services.”
The Canadian Mental Health Association (CMHA) reports that 20% of Canadians experience a mental health problem or illness every year. The CHMA notes that mental illness costs the Canadian social and healthcare system nearly $80 billion for 2021.
Subscribe to updates about Origin Therapeutics online at: https://originpsychedelics.com/
About Origin Therapeutics
Origin Therapeutics Holdings Inc. (CSE: ORIG Proposed) (the “Company” or “Origin Therapeutics”) is an actively managed investment issuer focused on making equity investments in psychedelics-related companies to provide investors with diverse exposure to the sector. The Company, led by a team of industry experts, leverages its management expertise, professional network, and due diligence process to identify leading and emerging global companies for its portfolio that are innovating in the sector and are supported by science. Learn more: https://originpsychedelics.com/
For Further Information:
Chief Executive Officer and Director
Origin Therapeutics Holdings Inc
For media inquiries, please contact: Brittany@Exvera.com
Forward-Looking Information and Statements
Certain statements in this news release related to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward- looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the closing of the Offering, the intended use of proceeds of the Offering, the filing of the Prospectus and the obtaining of receipts for the Prospectus. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks inherent in the Company’s business in general; (iii) that the proceeds of the Offering may need to be used for purposes other than as set out in this news release and other factors beyond the control of the Company. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward- looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by applicable law, the Company does not intend to update these forward-looking statements.
The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.